ImaginAb
ImaginAb is a clinical-stage biotechnology company developing CD8 ImmunoPET, a minibody-based radiopharmaceutical imaging agent used by pharmaceutical and biotech companies to non-invasively monitor CD8+ T-cell response in immuno-oncology clinical trials.
- Company typePrivate
- Founded2007
- HeadquartersInglewood, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ImaginAb does
ImaginAb, Inc. is a privately held, clinical-stage biotechnology company founded in 2007 and headquartered in Calabasas, California, with a European subsidiary established in 2021. The company develops radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform — engineered antibody fragments that retain the binding specificity of full-length antibodies while remaining biologically inert in vivo, making them suitable for PET imaging. Its lead product is CD8 ImmunoPET (89Zr crefmirlimab berdoxam), an 89Zr-labeled minibody that binds the CD8 receptor on human T-cells for non-invasive, quantitative whole-body imaging of immune status in immuno-oncology. The pipeline also includes a CD4 T-cell PET agent (89Zr-Df-IAB41M2C) for oncology and autoimmune disease applications and an optical PSMA agent (IR800-IAB2MA) for prostate and renal cancer surgical guidance. CD8 ImmunoPET is currently in Phase II clinical development, including the iPREDICT Phase IIb study targeting 80 patients across 22 sites in the US, Australia, and Europe.
ImaginAb monetizes its platform through non-exclusive technology licensing agreements, clinical trial supply contracts, and regional manufacturing and distribution partnerships. The company has executed 22+ such agreements with global pharmaceutical and biotech counterparties — including Pfizer, AstraZeneca, Takeda, Roche, Merck, Bayer, Boehringer Ingelheim, Chugai, Genmab, and Nektar — that use CD8 ImmunoPET to monitor immunotherapy response in their clinical development programs. Distribution and manufacturing is handled via partners including PharmaLogic (USA), Cyclotek (Australia), Monrol, and an exclusive China license with Yantai DongCheng Pharmaceutical Group. Pricing is not publicly disclosed; contracts are negotiated on a quote basis with pharmaceutical partners.
In January 2025, ImaginAb sold its pipeline of next-generation therapeutic candidates, its proprietary biologics platform, and its protein engineering and discovery research facility to Telix Pharmaceuticals Limited, retaining focus on the CD8 ImmunoPET imaging franchise. The company is venture-backed, having raised approximately $59.6M across five disclosed rounds since 2012, with investors including Adage Capital Management, Cycad Group, Norgine Ventures, Novartis Venture Fund, Mérieux Equity Partners, Nextech Invest, Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. Following the divestiture, ImaginAb operates as a single-asset radiopharmaceutical imaging company supported by a licensing and supply revenue model.
ImaginAb firmographics
Firmographics- Name
- ImaginAb
- Legal name
- ImaginAb, Inc.
- Website
- https://imaginab.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ImaginAb is a clinical-stage biotechnology company developing CD8 ImmunoPET, a minibody-based radiopharmaceutical imaging agent used by pharmaceutical and biotech companies to non-invasively monitor CD8+ T-cell response in immuno-oncology clinical trials.
- Ownership category
- akta.pro rank
ImaginAb industry classification
Industry- Product category
- Radiopharmaceutical Imaging Agents
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)
Keywords
Where ImaginAb is headquartered
LocationHeadquarters
- HQ city
- Inglewood
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
ImaginAb business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Technology Licensing: ImaginAb generates revenue through non-exclusive license agreements with pharmaceutical and biotech companies for use of their CD8 ImmunoPET technology in clinical trials. The company also sells manufacturing and distribution partnerships globally.
- Clinical Trial Services: Revenue from supplying CD8 ImmunoPET agent for clinical trials, including manufacturing, distribution, and technical support services for pharmaceutical partners.
- Product Supply: Supply of CD8 ImmunoPET imaging agent to clinical trial sites and pharmaceutical partners through manufacturing and distribution agreements.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
ImaginAb product offering
Product offeringCore offering
ImaginAb develops and manufactures radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform technology for non-invasive molecular imaging of immune cells. Its lead product CD8 ImmunoPET (89Zr crefmirlimab berdoxam) enables whole-body PET imaging of CD8+ T-cells to assess immunotherapy response in oncology patients. The company licenses this technology to pharmaceutical and biotech companies for use in clinical trials and supplies the imaging agent through manufacturing and distribution partnerships globally.
Product overview
ImaginAb is a clinical-stage biotechnology company developing a portfolio of radiopharmaceutical imaging agents based on its proprietary minibody platform technology. The core product is CD8 ImmunoPET (89Zr crefmirlimab berdoxam), an 89Zr-labeled minibody for PET imaging of CD8+ T-cells in immuno-oncology clinical trials. The portfolio also includes PSMA Optical Imaging (IR800-IAB2MA) for prostate and renal cancer surgical guidance, and CD4 T-cell PET Imaging (89Zr-Df-IAB41M2C) for oncology and autoimmune disease applications. The minibody technology uses engineered antibody fragments that maintain the specificity of full-length antibodies while remaining biologically inert in the body, used with PET and optical imaging technology.
Differentiator
Problem solved
Functional benefit
Products and services
- CD8 ImmunoPET (89Zr crefmirlimab berdoxam) Lead radiopharmaceutical imaging agent based on an 89Zr-labeled minibody that binds to the CD8 receptor on human T-cells, enabling quantitative, non-invasive whole-body PET imaging of CD8+ cell distribution in oncology patients. Used by pharmaceutical and biotech partners to diagnose immune status, measure immunotherapy efficacy, and predict patient outcomes in immuno-oncology clinical trials. Currently in Phase II clinical trials.
- PSMA Optical Imaging (IR800-IAB2MA) Fluorescent-labeled minibody imaging agent that binds the PSMA receptor for intraoperative fluorescence guidance during surgery, applied in prostate cancer and renal cancer surgical resection procedures.
- CD4 T-cell PET Imaging (89Zr-Df-IAB41M2C) PET imaging agent for visualizing CD4 T-cell trafficking in oncology and autoimmune disease applications, developed on the proprietary minibody platform.
Quantifiable outcome
- 80 patients enrolled across 22 sites in Phase IIb iPREDICT trial
- +1 more outcomes
Companies that use ImaginAb
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
ImaginAb technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ImaginAb partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered core, minor and flagship.
- Memorial Sloan Kettering Cancer CentercoreAgreement to support investigator-initiated trial led by Dr. Adam Schoenfeld assessing immune response after treatment with engineered tumor infiltrating lymphocyte therapy incorporating CD8 PET imaging.
- QuibimcorePartnership to revolutionize immune status diagnosis and immunotherapy prediction by combining CD8 ImmunoPET imaging with Quibim's AI-powered imaging analysis.
- Leucid BiominorLicense and supply agreement for CD8 ImmunoPET technology with Leucid Bio's clinical programs.
- TriSalus Life SciencesminorLicense and supply agreement for CD8 ImmunoPET technology to support TriSalus's therapeutic development programs.
- DynamiCure BiotechnologyminorLicense and supply agreement to provide CD8 ImmunoPET technology for DynamiCure's clinical development.
- Parthenon TherapeuticsminorLicense and supply agreement to advance new class of anti-cancer therapies' clinical development program using CD8 ImmunoPET.
- CyclotekcoreManufacturing and distribution agreement for CD8 ImmunoPET Agent in Australia to expand regional access and supply capabilities.
- PharmaLogiccoreManufacturing and distribution agreement for CD8 ImmunoPET agent (Zirconium 89 Crefmirlimab Berdoxam) in USA to ensure reliable supply for clinical trials.
- MonrolminorSupply, manufacturing and distribution partnership to support global production and delivery of CD8 ImmunoPET agent.
- Genmab A/ScoreSupply agreement to provide Genmab with investigational CD8 ImmunoPET agent for use in their clinical development programs.
- Yantai DongCheng Pharmaceutical GroupcoreExclusive license agreement to commercialize CD8 ImmunoPET agent in China to serve the pharma and healthcare community in the region.
- BayercoreLicense and supply agreement with Bayer for CD8 ImmunoPET technology to support Bayer's clinical development programs.
- ChugaiminorNon-exclusive license and supply agreement for CD8 ImmunoPET technology with Chugai Pharmaceutical.
- NeuvogenminorLicensing agreement for CD8 ImmunoPET technology to support clinical development of Neuvogen's novel therapeutic cancer vaccine candidates.
- AstraZeneca (Licensing)coreLicensing deal with AstraZeneca for CD8 ImmunoPET technology for use in clinical development.
- PfizerflagshipMulti-party collaboration agreement with three global pharmaceutical companies (Pfizer, AstraZeneca, Takeda) to further clinical development of CD8 ImmunoPET technology. Pfizer continues to be a great partner supporting development of innovative PET imaging technology.
- AstraZenecaflagshipPartnership with AstraZeneca to facilitate clinical development of their novel immunotherapies and advance the clinical utility of CD8 ImmunoPET technology.
- TakedaflagshipCollaboration with Takeda to innovate the tracking of immune responses associated with novel immuno-oncology therapies and relate these to anti-tumor responses in patients.
- RochecoreCollaboration with Roche, a leading pharmaceutical company focused on cancer treatment and diagnostics. ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq) to non-small cell lung cancer patients enrolled in ImaginAb's iPREDICT Phase IIb study.
- Nektar TherapeuticscoreImmuno-oncology license and clinical trial collaboration to use CD8 ImmunoPET technology in Nektar's clinical development programs.
- MerckcoreCollaboration with Merck, a global leader in immuno-oncology, to potentially accelerate clinical development of next generation immunotherapeutics using CD8 ImmunoPET.
- Boehringer IngelheimcoreLong-standing strategic collaboration with Boehringer Ingelheim to develop new technology for monitoring anti-tumor activity of the immune system. Partnership extended multiple times.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
ImaginAb competitors and assessment
Company assessmentDirect peers
- Telix Pharmaceuticals: Radiopharmaceutical company developing diagnostic and therapeutic agents, including immuno-PET programs. Telix's January 2025 acquisition of ImaginAb's therapeutic platform underscores its role as the most direct strategic peer in the immune-cell imaging space.
- Clarity Pharmaceuticals: Clinical-stage radiopharmaceutical company developing diagnostic and therapeutic agents (SAR-bisPSMA, SARTATE). Has an existing collaboration with ImaginAb (2020) and competes in the same immuno-oncology and PSMA imaging categories.
Broad incumbents
- Lantheus Holdings: Established radiopharmaceutical company with a portfolio of diagnostic imaging agents (e.g., PYLARIFY for PSMA PET). Lantheus competes for the same pharma trial imaging budgets and oncology imaging indications as ImaginAb, though at a much larger commercial scale.
- Curium Pharma: One of the largest radiopharmaceutical manufacturers globally, supplying diagnostic and therapeutic nuclear medicine products. Overlaps with ImaginAb in PET imaging agent production and distribution infrastructure.
- GE HealthCare: Diversified medical imaging company with a significant radiopharma and PET radiotracer business. Competes indirectly through its portfolio of oncology and neurology PET agents and through partnership channels with pharma trial sponsors.
- Bayer (Radiology / Algeta heritage): Bayer is both a current ImaginAb licensee (2021 license and supply deal) and a broader player in radiopharmaceuticals through its legacy Xofigo/radium-223 franchise and ongoing investments in targeted radionuclide therapy.
- Novartis / Advanced Accelerator Applications: Through Pluvicto and Lutathera, Novartis is the dominant player in therapeutic radioligand therapy. As a major immuno-oncology sponsor, Novartis is also a potential customer/competitor for predictive imaging biomarkers like CD8 ImmunoPET.
- Bracco Imaging: Global imaging agent manufacturer with a broad portfolio in contrast media and molecular imaging. Competes with ImaginAb in providing imaging solutions to hospital and pharma channels, though with a different technology base.
Emerging players
- Invicro (now part of Perceptive): Imaging CRO and radiopharmaceutical developer offering quantitative PET imaging services and biomarker development to pharma sponsors. Comparable to ImaginAb in serving I-O clinical trial imaging needs, though with a CRO/services orientation.
- SOFIE Biosciences: Radiopharma company developing diagnostic and therapeutic agents, with a portfolio overlapping ImaginAb's immune-cell imaging focus. Both companies are based in Southern California and pursue a similar translational imaging strategy in oncology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ImaginAb social profiles
Digital presenceImaginAb financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImaginAb leadership team
Management profileNumber of profiles
Profiles15 records
ImaginAb subsidiaries and ownership
Company hierarchySubsidiaries1 record
ImaginAb funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImaginAb M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImaginAb
What does ImaginAb do?
ImaginAb develops and manufactures radiopharmaceutical imaging agents based on its proprietary minibody and cys-diabody platform technology for non-invasive molecular imaging of immune cells. Its lead product CD8 ImmunoPET (89Zr crefmirlimab berdoxam) enables whole-body PET imaging of CD8+ T-cells to assess immunotherapy response in oncology patients. The company licenses this technology to pharmaceutical and biotech companies for use in clinical trials and supplies the imaging agent through manufacturing and distribution partnerships globally.
Is ImaginAb a public or private company?
ImaginAb is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImaginAb founded?
ImaginAb was founded in 2007. It employs 11 to 50 people.
Where is ImaginAb based?
ImaginAb is headquartered in Inglewood, United States, in the North America region.
How does ImaginAb make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are clinical Trial Services and product Supply.
Who are ImaginAb's main competitors?
Direct peers on record are Telix Pharmaceuticals and Clarity Pharmaceuticals. Broad incumbents are Lantheus Holdings, Curium Pharma, GE HealthCare, Bayer (Radiology / Algeta heritage), Novartis / Advanced Accelerator Applications and Bracco Imaging. Emerging players are Invicro (now part of Perceptive) and SOFIE Biosciences.
Does ImaginAb have an API?
No public API is recorded for ImaginAb.
What industry is ImaginAb in?
ImaginAb's product category is Radiopharmaceutical Imaging Agents. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325412 and its SIC code is 2834.